Document Detail


A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome).
MedLine Citation:
PMID:  17118734     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: 'Mirror syndrome' (Ballantyne's syndrome) refers to the association of fetal hydrops with placentomegaly and severe maternal edema. Preeclampsia occurs in approximately 50% of these cases. Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), an anti-angiogenic factor, has been implicated in the pathophysiology of preeclampsia (PE). OBJECTIVE: The objective of this study was to determine if the maternal plasma concentration of sVEGFR-1 is elevated in patients with mirror syndrome. STUDY DESIGN: This case-control study included patients with uncomplicated pregnancies (n = 40) and those with mirror syndrome (n = 4) matched for gestational age. Mirror syndrome was defined as fetal hydrops and severe maternal edema. Maternal plasma sVEGFR-1 concentrations were determined using specific enzyme-linked immunosorbent assays. Immunohistochemistry of sVEGFR-1 on villous trophoblasts was also performed in samples from one patient with mirror syndrome and compared with those from a patient with spontaneous preterm delivery matched for gestational age. Non-parametric statistics were used for analysis (p < 0.05). RESULTS: (1) The median maternal plasma concentration of sVEGFR-1 was significantly higher in patients with mirror syndrome than in the control group (median: 3974 pg/mL, range: 3083-10 780 vs. median: 824 pg/mL, range: 260-4712, respectively; p < 0.001). (2) All patients with mirror syndrome had sVEGFR-1 concentrations above the 95th percentile for gestational age. Syncytiotrophoblast, especially syncytial knots, showed strong staining with antibodies against sVEGFR-1 in placental samples from the patient with mirror syndrome, but not in those from the patient with spontaneous preterm delivery. CONCLUSION: High maternal plasma concentrations of sVEGFR-1 were observed in mirror syndrome. We propose that this anti-angiogenic factor may participate in the pathophysiology of this syndrome. Thus, maternal plasma determination of sVEGFR-1 may help to identify the hydropic fetus that places the mother at risk for preeclampsia.
Authors:
Jimmy Espinoza; Roberto Romero; Jyh Kae Nien; Juan Pedro Kusanovic; Karina Richani; Ricardo Gomez; Chong Jai Kim; Pooja Mittal; Francesca Gotsh; Offer Erez; Tinnakorn Chaiworapongsa; Sonia Hassan
Related Documents :
12172534 - Invasive group a streptococcus associated with an intrauterine device and oral sex.
156304 - "prune belly" syndrome.
20186814 - Histology and synchrotron radiation-based microtomography of the inner ear in a molecul...
8607954 - Temporal bone study of down's syndrome.
8457924 - Congenital duplication.
9332934 - Budd-chiari syndrome as late complication of secundum atrial septal defect closure.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural    
Journal Detail:
Title:  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians     Volume:  19     ISSN:  1476-7058     ISO Abbreviation:  J. Matern. Fetal. Neonatal. Med.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-11-22     Completed Date:  2007-02-23     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  101136916     Medline TA:  J Matern Fetal Neonatal Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  607-13     Citation Subset:  IM    
Affiliation:
Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland, Michigan, Detroit, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Case-Control Studies
Edema / metabolism*
Female
Gestational Age
Humans
Hydrops Fetalis / metabolism*
Placenta / pathology
Pregnancy
Pregnancy Complications / blood*,  metabolism*
Vascular Endothelial Growth Factor Receptor-1 / blood*,  metabolism*
Chemical
Reg. No./Substance:
EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The pathophysiology of trauma in pregnancy: a review.
Next Document:  Endocrine regulation in asymmetric intrauterine fetal growth retardation.